Allergan goes in early for MAP as FDA deliberates over second-pass Levadex
This article was originally published in Scrip
Executive Summary
Allergan has decided to gamble on an early offer for partner MAP Pharmaceuticals. Neurology-focused MAP has Levadex (dihydroergotamine), a new orally inhaled migraine drug, currently under review at the US FDA.